Cannabidiol and Cancer
Investigative retrospective safety reporting, using cannabidiol in oncology patients.
Many patients with cancer take cannabinoids in various forms.
Under the direction of our consultant oncologists, the aim is to examine data based on supplies of cannabinoids made to patients – using standardised dosing – extrapolated from in-vitro studies.
The primary aim of this investigative arm of our research is to determine overall safety at the doses prescribed.
This will be retrospective and consider the other medicines patients have been prescribed.
Patients from the following groups are identified specifically, however, many other cancers are included in the study:
- Bladder Cancer
- Breast Cancer
- Carcinoid Colon & Rectal Cancer
- Liver Cancer
- Lung Cancer (Non-Small Cell)
- Lymphocytic Leukemia (chronic)
- Lymphoma (Hodgkin’s and Non-Hodgkin’s)
- Malignant Melanoma
- Multiple Myeloma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer (untreated)
- Renal Cell Carcinoma
- Throat Cancer
- Uterine Cancer